Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 2/20 | 0.56 |
| ▸ | TDO2 | P48775 | 3/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | CD38 | P28907 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | FADS1 | O60427 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.40 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071379 | 0.88 | PTK6 (0.59) | PTK6TDO2IDO1CD38GRM4 | |
| SCHEMBL6071699 | 0.79 | FADS1 (0.68) | PTK6CD38EGFRFADS1ERBB2 | |
| SCHEMBL4740984 | 0.78 | PTK6 (0.53) | PTK6TDO2IDO1CD38GRM4 | |
| SCHEMBL23117519 | 0.76 | CD38 (0.62) | PTK6IDO1CD38EGFRFADS1 | |
| SCHEMBL4741727 | 0.73 | FADS1 (0.68) | PTK6GRM4EGFRFADS1ERBB2 | |
| SCHEMBL4740968 | 0.73 | CD38 (0.65) | PTK6TDO2CD38EGFRFADS1 | |
| SCHEMBL4961504 | 0.72 | CD38 (0.61) | PTK6CD38EGFRFADS1ABCG2 | |
| SCHEMBL6086853 | 0.70 | GAA (0.50) | TDO2IDO1GRM4FADS1 | |
| SCHEMBL5948621 | 0.70 | GRM1 (0.67) | PTK6TDO2IDO1CD38GRM4 | |
| SCHEMBL4787800 | 0.70 | CD38 (0.64) | PTK6CD38EGFRFADS1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | PTK6 180/4885TDO2 970/4885IDO1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.